Pharma Striking Early Stage Deals With AcademiaWith the price of developing a new drug and bringing it to market running into the hundreds of millions and up to more than $2.5 billion, pharmaceutical companies are forging partnerships with universities to help cut the cost and hasten the process.Read the rest of this entry »
Academic researchers and major drug companies have worked together in the past, typically at the clinical trial stage. Now, big pharma is looking to partner with universities ...
Report Shows Workforce Drug Use Increased In 20164.2% of American workers tested positive for drugs last year, the highest rate in a dozen years, according to Quest Diagnostics.Read the rest of this entry »
The company, one of the largest providers of medical and diagnostic tests in the U.S., issued its annual Quest Diagnostics Drug Testing Index in May. The company said it found cocaine, marijuana and methamphetamine use was up across the nation.
“This year’s findings are remarkable because ...
The Highest Paying Life Sciences Job You Never Heard OfWhat's the highest paying job in biotech you've probably never heard of?Read the rest of this entry »
OK. That's sort of a trick kind of question, since you can't really answer it if you've never heard of it. So we'll tell you what BioSpace said the job is: Medical Science Liaison.
The site, which describes itself as a "digital hub for news and careers" in life sciences, said the ...
3D Printers Are Pharma's 'Next Great Step'3D printing came to the pharmaceutical industry two years ago when the FDA gave Aprecia Pharmaceuticals approval to use the technology to manufacture its epilepsy medication Spritam.Read the rest of this entry »
Though adoption of 3D pharmaceutical manufacturing is in its infancy, within a decade the medical application of the technology could exceed $1.9 billion, an estimate that may already be outdated as the pace of development has been accelerating steadily. Before drug companies ...
How the Pharmaceutical Industry May Track Every PillA technology most commonly linked to the cryptocurrency payment system Bitcoin, may prove to be the key to rooting out counterfeit prescription drugs.Read the rest of this entry »
Blockchain startup Chronicled and supply chain consultant, The LinkLab, last week announced a pilot "track and trace" program for the pharmaceutical industry.
The industry is under a 2023 deadline to develop and implement an electronic, interoperable system to identify and trace prescription drugs throughout the U.S ...
The Challenges of Clinical Trial RecruitingIn a world where clinical trials are becoming increasingly complex, one of the first challenges pharmaceutical companies, as well as other medical researchers, face is recruiting sufficient number of subjects to produce valid results.Read the rest of this entry »
Though getting more difficult all the time, by no means is this a new problem. Louis Lasagna, a pioneer in clinical pharmacology, came up with what is now called Lasagna's Law, which, in essence says ...
How the New Health Economy is Changing PharmaDeclaring that we're in a "New Health Economy," the global consulting firm PwC says life sciences and drug companies are facing multiple new challenges that are turning old business models on their head.Read the rest of this entry »
There are "three pivotal healthcare and pharma industry developments... that pharma companies must confront in 2017," says PwC in an article on the firm's Strategy& site. As Pwc describes them, the three are:
- The year ...
Pharma's 2016 TV Spend Topped $2.2 BillionAnyone who watches TV, especially daytime TV, couldn't help but wonder just what kind of miracle drug Humira must be. Ads for the drug aired more than 69,000 times last year.Read the rest of this entry »
In order of how much its manufacturer, AbbVie spent touting Humira's uses:
- Arthritis -- $173 million
- Crohn's and colitis -- $118 million
- Psoriasis -- $54 million.
Among the top 20 brands advertised on TV, Humira's $344 million ...
More Biotech PhDs Are Starting CompaniesThe boom in biotech funding coupled with the paucity of academic jobs is tempting young scientists to skip post-doc research in favor of heading straight into business.Read the rest of this entry »
The science journal Nature says there's a "vanguard of young biomedical scientists who have started companies instead of taking the conventional academic path and pursuing postdoctoral studies after their PhDs."
Where once investors would only fund companies started by established professors who ...
Pharma CEOs See Opportunity Ahead"Pharma's future have never looked more promising -- or more ominous." That cautionary statement topping the front page of the last report in PWC's Pharma 2020 series could still stand today as a summary of the entire pharmaceuticals and life sciences industry.Read the rest of this entry »
PWC's most recent survey of the CEOs of 87 of the largest pharmaceutical companies found optimism about the growth of their individual revenues as well as ...